IL2 and graft versus host disease: Similarly, most clinical trials of Ld-IL2 therapy in other autoimmune diseases measured CD4+ T cells subsets, particularly TREG cells as the primary endpoints, including GVHD [38,39], Vasculitis [40], type 1 diabetes [41,42] and Sjögren’s syndrome [43].